Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study
Clinical Reviews in Allergy and Immunology, 06/25/09
Filippini M et al. – Study shows that anti-TNFα treatment reduced disease activity and led to functional improvement in both elderly and younger patients, although the baseline difference in HAQ remained statistically significant at the end of the follow-up. The elderly patients experienced more infective events.
Methods- A comparison of the efficacy and safety of anti-TNF agents in elderly (aged ≥65 yrs) and younger pts (aged 18–65 yrs) with active RA
- 1,114 RA pts, followed-up for >6 mo, were divided into 2 cohorts on the basis of their age to evaluate 3-yr outcomes and treatment discontinuations
- Drug effectiveness was assessed by DAS28 and EULAR response, functional status (HAQ) and serological parameters (ESR) at baseline and during therapy
- Safety was evaluated on the basis of drug discontinuation rates
- At baseline, the elderly pts showed greater disease activity and loss of joint function
- During therapy, clinical and laboratory parameters improved in both groups w/o any difference between them
- Difference in HAQ remained after 36 mo of treatment
- Anti-TNFα therapy was discontinued by 42% elderly and 36.6% of younger pts because of loss of efficacy, severe adverse events or other reasons
- Number of AEs was higher in the elderly patients
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/23/09
Update of the guidelines for lupus anticoagulant detection
Journal of Thrombosis and Haemostasis, 09/28/09
Romiplostim in chronic immune thrombocytopenic purpura
Clinical Therapeutics, 10/23/09
Today in Rheumatic/Autoimmune...keeping you current
Receive free subspecialty "5-minute updates" via email
Latent Autoimmune Diabetes in Adults
Journal of Clinical Endocrinology and Metabolism, 10/21/09
Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the age of remission?
Expert Opinion on Investigational Drugs, 10/13/09
Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, 11/05/09
Sponsor
Article Search
Sponsor


See Latest Articles


